Back to directory
Innovation in Sight
DallasFounded 2023
HealthcareBiotech
🟢 Raising pre-seed — $1.0M target
Activity
See allSee something off about this company?
Innovation in Sight
Clearsight and Covalent Medical have signed an LOI for $63M over 5years. ClearSight will manufacture and produce 6 unique SKUs for Covalent Medical to commercialize and sell. The agreement will entail 3 products under the Focus Tears brand family (www.focusvitamins.com), which will be sold directly through Ophthalmologists and Optometrists to patients suffering from Dry Eye, Wearing contact lenses and Pink Eye. They will also launch 3 SKUs under a separate brand, Alivyo, for sale through the Retail Channel (CVS, Walgreens, etc.).
See something off about this company?
ClearSight will manufacture and provide a private-label version of our innovative over-the-counter (OTC) pink eye treatment. Cartwheel will package and sell this product to major retail chains in the US under its brand. Cartwheel is set to launch its lice treatment in 2026 and will focus on introducing the ClearSight formulation in 2027.
ClearSight Therapeutics presented at the 2025 iC³® Life Science & Healthcare Innovation Summit on September 17th, and barring a tech issue that prevented our slides from loading (not our fault btw), it was a smashing success! Startup life is full of curveballs and pivots and to be honest, I rather enjoyed the opportunity to talk directly to the audience about the amazing products that we are developing that treat real Eye Care conditions without the distraction of PowerPoint over my shoulder!
We have finished developing our formulation and conducted pre-clinical tests for antibacterial, antifungal, and antiviral activity. We have also started our key pre-clinical biofilm study and expect to see results soon.
Established a partnership with Unither Pharma, Rochester, NY, for the development and manufacturing of our clinical and commercial products.
ClearSight Therapeutics is dedicated to enhancing patient outcomes by developing innovative over-the-counter (OTC) products for individuals suffering from Dry Eye Disease, Contact Lens Rewetting, and Acute Infectious Conjunctivitis (commonly known as “Pink Eye”). We leverage our proprietary dual-action formulation, which combines an artificial tear with a potent antimicrobial biopolymer. Our products will be the first in their class to address biofilm complications associated with Dry Eye and extended contact lens wear. Furthermore, our Pink Eye treatment will be the first OTC medication able to treat viral pink eye, which accounts for approximately 80% of cases.
ClearSight’s proprietary, patent-pending formulation features a powerful antimicrobial biopolymer that effectively targets and eliminates bacterial, fungal, and viral infections associated with pink eye. Unlike antibiotics, this biopolymer acts on the bacterial cell wall, preventing the development of bacterial resistance. Furthermore, ClearSight’s biopolymer can remove biofilm, which is a challenging complication often seen in Dry Eye Disease and infections related to contact lens use.
Patrick Smale
founder